Research Article
Clinical Characteristics and Spermatogenesis in Patients with Congenital Hypogonadotropic Hypogonadism Caused by FGFR1 Mutations
Table 3
Sperm production during therapy.
| Groups | FGFR1 mutation (n = 14) | Mutation-negative (n = 24) | |
| Mean follow-up time (months) | 26.36 ± 8.54 | 22.54 ± 8.74 | 0.199 | Cumulative success rate of achieving first sperm appearance in 1 year | 35.71% | 68.75% | 0.047 | Cumulative success rate of achieving first sperm appearance in 2 years | 75.89% | 82.14% | 0.160 | Testicular volume (mL) | 7.00 (4.75–12.00) (n = 14) | 10.56 ± 4.82 (n = 24) | 0.098 | Testosterone (ng/dL) | 366.02 ± 167.03 (n = 14) | 362.27 ± 212.86 (n = 24) | 0.956 | Testosterone in pulsatile GnRH therapy (ng/dL) | 286.95 ± 130.11 (n = 4) | 304.54 ± 167.03 (n = 13) | 0.857 | Testosterone in gonadotropin therapy (ng/dL) | 397.65 ± 189.78 (n = 10) | 431.76 ± 247.42 (n = 11) | 0.729 | FSH in GnRH pulsatile therapy (IU/L) | 9.77 ± 6.20 (n = 4) | 9.75 ± 4.01 (n = 13) | 0.993 | LH in GnRH pulsatile therapy (IU/L) | 8.46 ± 3.31 (n = 4) | 7.59 ± 4.07 (n = 13) | 0.737 |
|
|